Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13477873 | 0.91 | HPGD (0.34) | HPGDHTTSMN1; SMN2MGLL | |
| SCHEMBL13748838 | 0.91 | HPGD (0.34) | HPGDHTTSMN1; SMN2MGLL | |
| SCHEMBL12421788 | 0.91 | HPGD (0.35) | HPGDHTTSMN1; SMN2MGLLKMT2A | |
| SCHEMBL12107373 | 0.87 | MGLL (0.34) | HPGDHTTSMN1; SMN2MGLLKMT2A | |
| SCHEMBL277464 | 0.84 | ALDH1A1 (0.33) | MGLLALDH1A1MAPT | |
| SCHEMBL2607896 | 0.84 | MGLL (0.32) | MGLL | |
| SCHEMBL10075274 | 0.83 | SMN1; SMN2 (0.35) | HPGDSMN1; SMN2MGLLKMT2AATM | |
| SCHEMBL14464255 | 0.83 | MGLL (0.36) | HTTMGLLKMT2AATMALDH1A1 | |
| SCHEMBL15502949 | 0.83 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL15677157 | 0.83 | MGLL (0.31) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401948-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2021-12-30 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-8962549-B2 | Polymeric benzyl carbonate-derivatives | BAXTER INTERNATIONAL INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | NEKTAR THERAPEUTICS | 2015-02-05 | — | — | US | disclosed |
| US-8889831-B2 | Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate | NEKTAR THERAPEUTICS (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE SA (CH) | 2014-05-08 | — | — | US | disclosed |
| US-8653131-B2 | Polymeric benzyl carbonate-derivatives | BAXTER HEALTHCARE S.A. (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8586711-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-19 | — | — | US | disclosed |
| US-8519102-B2 | Polymer Factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-08-27 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100004428-A1 | Method of Preparing Propionic Acid-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7608663-B2 | reacting a water soluble and non-peptidic polymer comprising at least one hydroxyl group with a tertiary alkyl acrylate in the presence of a catalyst to form a propionic acid ester of the polymer; acid treatment; may be further derivatized; particularly propionic acid-terminated poly(ethylene glycol)s | NEKTAR THERAPEUTICS (US) | 2009-10-27 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | F8, F13B, F13A1 | HPGD 1338/4885HTT 1519/4885SMN1; SMN2 1303/4885 |
| US-20210401948-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | HPGD 1782/4885HTT 2510/4885SMN1; SMN2 1402/4885 |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | HPGD 2385/4885HTT 2103/4885SMN1; SMN2 3568/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | HPGD 1782/4885HTT 2510/4885SMN1; SMN2 1402/4885 |
| US-20100004428-A1 | Method of Preparing Propionic Acid-Terminated Polymers | PAM, PARG, ACR | HPGD 653/4885HTT 509/4885SMN1; SMN2 3647/4885 |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | SI, SLC1A5, BCAT1 | HPGD 1683/4885HTT 3362/4885SMN1; SMN2 2197/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | HPGD 1182/4885HTT 1538/4885SMN1; SMN2 1544/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | HPGD 1011/4885HTT 798/4885SMN1; SMN2 3529/4885 |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | SI, SLC1A5, BCAT1 | HPGD 1683/4885HTT 3362/4885SMN1; SMN2 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.